TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Rezolute's stock dropped 90% after its Phase 3 trial for ersodetug failed to meet primary and secondary endpoints in treating hypoglycemia caused by hyperinsulinism, prompting a shareholder investigation.

Insights
RZLT   negative

Stock price crashed 90% due to clinical trial failure, contradicting previous investor assurances about drug efficacy and market potential